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PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation
A new approach to the management of non-small-cell
lung cancer (NSCLC) has recently emerged that
works by manipulating the immune checkpoint con-
trolled by programmed death receptor 1 (PD-1) and
its ligand programmed death ligand 1 (PD-L1). Sev-
eral drugs targeting PD-1 (pembrolizumab and nivo-
lumab) or PD-L1 (atezolizumab, durvalumab, and
avelumab) have been approved or are in the late
stages of development. Inevitably, the introduction of
these drugs will put pressure on healthcare systems,
and there is a need to stratify patients to identify
those who are most likely to benefit from such treat-
ment. There is evidence that responsiveness to PD-1
inhibitors may be predicted by expression of PD-L1
on neoplastic cells. Hence, there is considerable inter-
est in using PD-L1 immunohistochemical staining to
guide the use of PD-1-targeted treatments in patients
with NSCLC. This article reviews the current knowl-
edge about PD-L1 testing, and identifies current
research requirements. Key factors to consider
include the source and timing of sample collection,
pre-analytical steps (sample tracking, fixation, tissue
processing, sectioning, and tissue prioritization), ana-
lytical decisions (choice of biomarker assay/kit and
automated staining platform, with verification of
standardized assays or validation of laboratory-
devised techniques, internal and external quality
assurance, and audit), and reporting and interpreta-
tion of the results. This review addresses the need for
integration of PD-L1 immunohistochemistry with
other tests as part of locally agreed pathways and
protocols. There remain areas of uncertainty, and
guidance should be updated regularly as new infor-
mation becomes available.
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Introduction
Worldwide, almost 1.6 million people die from lung
cancer every year.1 Non-small-cell lung cancer
(NSCLC) accounts for ~85% of all cases2 but, until
recently, options for managing this disease were lim-
ited and often ineffective. For the ~25% of patients with
early-stage disease at diagnosis, surgery or radical
radiotherapy is possible. However, for the majority, in
whom disease is disseminated, options are typically
confined to chemotherapy or palliative radiotherapy.3
The advent of tyrosine kinase inhibitors (TKIs) a
decade ago led to significant progress in the manage-
ment of NSCLC, heralding a new and elegant
approach to treatment, in which patient subgroups
with particular genetic abnormalities can be accu-
rately targeted.4 Treatment with drugs that are active
against sensitizing mutations in the epidermal growth
factor receptor (EGFR) (such as erlotinib, gefitinib,
and afatinib) or against anaplastic lymphoma kinase
(ALK) rearrangements (such as crizotinib and ceri-
tinib) is now standard. However, because these TKIs
target only those clones of neoplastic cells with a par-
ticular genetic aberration, tumours often evolve to
escape their inhibitory effect, and previously hidden
or new mutations eventually emerge to render the
tumour resistant.5 In a sense, these drugs are com-
promised by their own specificity.
A new approach to the management of NSCLC,
involving immune checkpoint inhibitors, has emerged
recently. These drugs do not rely on specific targeting
of the tumour, but instead work by disabling the abil-
ity of the tumour to evade the immune response of
the host, which would normally recognize the neo-
plastic population as foreign and subject it to immune
destruction.6 Several immune checkpoint inhibitors
involving ligand–receptor interactions appear to be
relevant in protecting tumours from immune attack.
The immunology is complex, involving antigen-pre-
senting cells, T lymphocytes of several subsets, and
neoplastic cells. The profound local immune suppres-
sion present in tumours is orchestrated by cytokines
and other molecules produced by neoplastic cells or
expressed on their surface (Figure 1).
With regard to NSCLC, most interest has centred
on the interaction between programmed death recep-
tor 1 (PD-1) and its ligand programmed death ligand 1
(PD-L1; also known as B7 homologue 1, encoded by
the gene CD274). PD-1 is expressed on the surfaces
of immune cells, particularly activated T lympho-
cytes. Its normal function is to down-modulate
unwanted or excessive immune responses, including
autoimmune reactions. PD-L1 is a transmembrane
protein that is expressed at low levels by various
healthy cell types (e.g. immune, vascular, endothelial
and epithelial cells) but at high levels by some neo-
plastic cells. In the context of NSCLC, the binding of
PD-1 and PD-L1 protects the tumour from immune
attack.7 Inhibition of either receptor or ligand by
monoclonal antibodies removes this protective effect,
exposing the tumour to immune destruction.
This strategy, known as ‘immune modulation’ or
‘immune checkpoint inhibition’, has shown great pro-
mise in human studies, and several drugs have been
approved or are in the late stages of development.
These include both anti-PD-1 agents (e.g. pem-
brolizumab and nivolumab) and anti-PD-L1 agents
(e.g. atezolizumab, durvalumab, and avelumab).8 How-
ever, there remain important and unresolved questions
about the prediction of which patients are most likely
to benefit from such drugs.9 In some cancer types, such
as Hodgkin lymphoma, most tumours appear to
express PD-L1, and hence there may be no need to
stratify patients according to expression. In other can-
cers, such as melanoma, PD-1 blockade is effective
regardless of PD-L1 status, and again there appears to
be no need to evaluate PD-L1 expression. However, for
a third group of cancers, including NSCLC, there is evi-
dence that responsiveness to PD-1 inhibitors, such as
pembrolizumab and nivolumab, may be predicted by
expression of PD-L1 on neoplastic cells. The role of
non-neoplastic cellular expression of PD-L1, particu-
larly on tumour-infiltrating lymphocytes (TILs), is still
being studied and is a matter of much debate.
As these targeted agents become available for wide-
spread clinical use amidst the constraints of restricted
healthcare budgets and the need to optimize resource
allocation, PD-L1 testing could become enormously
important in NSCLC management. To ensure that
treatment decisions based on PD-L1 expression are
consistent and objective, standards for PD-L1 testing
need to be established. At a meeting in London in Octo-
ber 2015, a group of experts was brought together to
discuss current knowledge about PD-L1 testing and to
assess the research that is still required as a priority, in
order for reliable and accurate testing to be ensured.
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Figure 1. Role of programmed death receptor 1 (PD-1) in cancer immunology. For activation and transformation into immune effector cells,
quiescent T cells require stimulation by major histocompatibility complex (MHC) proteins on antigen-presenting cells (APCs). However,
uncontrolled stimulation could result in adverse effects on host cells (e.g. manifesting as hypersensitivity reactions). To control these effects,
T cells are activated only in the presence of additional signalling from ‘co-stimulatory’ interactions, whereas activation is inhibited by ‘co-
inhibitory’ interactions. PD-1 is an example of a co-inhibitory receptor, which, when activated by its ligand [usually programmed death
ligand 1 (PD-L1) on cancer cells], blocks intracellular signalling along the phosphatidylinositol 3-kinase (PI3K)–Akt pathway. As a result,
the T cell is prevented from proliferating or producing cytokines, and the immune response is suppressed.
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This article summarizes the findings of that meeting,
some of the points from which have been taken up by
the Blueprint study proposal, which may provide the
answers to some of the questions posed here (http://
www.aacr.org/AdvocacyPolicy/GovernmentAffairs/
Documents/FDA-AACR-ASCO-Complexities-in-Perso-
nalized-Medicine-Blueprint-Proposal.pdf).
Sample collection
S A M P L I N G M E T H O D
Acquisition of sufficient lung cancer tissue for exami-
nation is the key first step in PD-L1 testing. Several
techniques are available, including flexible bron-
choscopy, computed tomography (CT)-guided needle
biopsy, and endobronchial ultrasound-guided trans-
bronchial needle aspiration (EBUS-TBNA). All of these
methods have yields of >85% for lung cancer diagno-
sis, with minimal complication rates.
A systematic review of CT-guided fine needle aspira-
tion and core needle biopsy showed no differences
between the two techniques in terms of diagnostic yield
and rates of complications (pneumothorax or haemor-
rhage).10 However, only two of the studies included in
the analysis were published after 2005, and neither of
these was randomized. Few studies have documented
the adequacy of samples taken for lung cancer subtyp-
ing derived from bronchoscopy, CT-guided biopsy, or
aspiration, but complication rates of 17% from CT-
guided intrathoracic research biopsy have been
reported.11 In a study of CT-guided lung biopsies taken
with a 20-gauge needle before randomization in an
NSCLC clinical trial, specimens from 83% of patients
had adequate tumour tissue for analysis of the required
biomarkers.12 The rates of pneumothorax and inter-
costal drainage were 15% and 9%, respectively.
The use of EBUS-TBNA as a primary diagnostic
and staging tool for lung cancer has expanded rapidly
in recent years.13 A multicentre, real-world study of
774 patients with known or suspected lung cancer
found the sensitivity of this procedure to be 88%,
with a diagnostic accuracy of 91%.14 EGFR mutation
testing was possible in 90% of cases in which it was
requested. Similarly, in a prospective study of 451
patients undergoing EBUS-TBNA, the sensitivity (87–
93%) and procedural tolerance were high, and over-
all complication rates were low (<9%, mostly minor),
regardless of patients’ age and performance status.15
Sufficient tissue was collected for morphological eval-
uation and EGFR mutation analysis in >97% of cases.
Given its favourable safety and efficacy profile,16
EBUS-TBNA is now regarded as the most useful
approach for repeated lung cancer tissue sampling.
The suitability of specimens from EBUS-TBNA for
assessment of PD-L1 status is currently being investi-
gated in terms of viable tumour cell numbers for
interpretation and validation of PD-L1 assays on
EBUS-TBNA specimens.
T U M O U R H E T E R O G E N E I T Y A N D E V O L U T I O N
There is increasing evidence of heterogeneity both
within the primary tumour and between primary
tumours and metastases. For example, in a study com-
paring EGFR status in primary lung cancer specimens
and lymph node metastases, there was discordance in
17% of cases.17 Thus, a biopsy from a single site may
not be representative of overall tumour biology and
burden. It is not yet known whether this phenomenon
affects PD-L1 status, although this seems likely.
Techniques such as EBUS-TBNA or CT-guided co-
axial biopsy facilitate intratumoral or involved lymph
node sampling as a result of deeper core sampling than
is obtained with superficial pinch biopsies at bron-
choscopy. With additional technologies, such as navi-
gational bronchoscopy in combination with EBUS-
TBNA, sampling of the primary tumour and multiple
intrathoracic lymph nodes during a single procedure
can identify the heterogeneity of regional metastatic
disease to a far greater extent than was previously pos-
sible. Assessment of TILs is not possible in lymph node
samples, and is difficult in cytological tumour samples.
In addition to the tumour heterogeneity present at a
given time, tumours can also evolve over time. It is
therefore unclear whether the presence of a marker
such as PD-L1 in a biopsy taken at the initiation of
first-line therapy will remain predictive of treatment
response in the second-line setting. However, re-biopsy
of tumours in patients with advanced NSCLC is not
routinely performed, owing to patient health or unwill-
ingness, or technical limitations. In a recent study of
repeated CT-guided biopsy following disease progres-
sion after first-line therapy, suitable tissue for molecu-
lar analysis was obtained in 80% of cases, and 14% of
patients experienced complications.18 In a multicentre
study of 100 patients following treatment for advanced
NSCLC, re-biopsy was not possible in 20% of cases, and
provided inadequate tumour cells in 26% of cases.19
Nonetheless, the data demonstrate that it is possi-
ble to perform repeat biopsy with CT or advanced
bronchoscopic modalities. A study of the feasibility
and clinical utility of re-biopsy in routine practice
found that it was useful for guiding treatment in
advanced NSCLC in 30% of cases, leading the study’s
authors to recommend re-biopsy whenever possible.19
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However, the applicability of these findings to PD-L1
is unknown, and data specific to PD-L1 testing are
not currently available.
Pre-analytical considerations
Pathologists are required to provide an increasing vari-
ety of ever more complex diagnostic information from
small biopsies in NSCLC and other diseases. It is essen-
tial to pay attention to pre-analytical considerations,
including fixation and sample processing, to ensure
the reliability of results. PD-L1 testing should be com-
patible with other tests required and their analysis.
In some cases, central laboratories may offer all of
the necessary testing and provide a useful option.
However, centralized testing may be problematic if
specimens need to be split and sent to separate labora-
tories for different tests. Distribution of specimens to
distant sites can prove difficult if clinical teams require
a short turnaround time. Current guidance for molecu-
lar pathology from the European Society for Pathology
and the UK Royal College of Pathologists indicates that
this choice should be a multidisciplinary decision based
on local expertise, need, cost, and tissue availability.20
Tissue for PD-L1 testing does not require any spe-
cial preparation. The key pre-analytical steps are sim-
ilar to those for other immunohistochemical and
molecular tests, and include sample tracking, fixation,
tissue processing, sectioning, and tissue prioritization.
S A M P L E T R A C K I N G
The early use of bar-coding is strongly advocated, as
this minimizes the risk of sample confusion, especially if
the sample needs to be split or sent away, as this could
result in patients receiving incorrect treatment. It is also
essential that laboratories operate in accordance with
ISO15189 to avoid such issues. Nevertheless, misidenti-
fication continues to be commonly encountered within
External Quality Assessment (EQA) schemes.
F I X A T I O N
Small biopsies fix rapidly in formalin, and there is stan-
dardization across pathology laboratories in the use of
10% neutral buffered formalin. To provide optimal fix-
ation, it is good practice to incise larger specimens
where possible, respecting resection margins. In the
lung, the airways can also be used to inflate specimens
with formalin, ensuring that there is no delay in
tumour fixation. In general, at least 5 h for biopsies
and 24–72 h for surgical excisions is advised. Cross-
linking of proteins in the tissue resulting from overfixa-
tion can create problems for the penetration of anti-
body reagents used in both immunohistochemistry
(IHC) and molecular pathology.
T I S S U E P R O C E S S I N G
The use of automated tissue processors is now ubiqui-
tous. These instruments allow exposure of tissue sam-
ples to fixative, alcohol dehydration, xylene or
equivalent, and paraffin wax, under temperature and
pressure (vacuum) control. However, individual
departments vary in their exposure time and temper-
ature preferences, which can affect the results of IHC
and nucleic acid extraction for molecular pathology.
Manufacturers of such instruments should attempt to
standardize their methods, and further standardiza-
tion of processing within histopathology departments
would be advantageous.
S E C T I O N I N G
Where possible, sections of 3–4 lm should be cut
shortly before IHC is performed. Storage of samples for
up to 1 week may have no adverse effect on staining
results, although further data are required to confirm
this. Even though assay manufacturers have shown
cut-sample stability of up to 6 months (Dako UK Ltd,
Ely), this approach is not recommended, as there may
still be tissue degradation and, more importantly,
patients are likely to require treatment decisions much
sooner.
T I S S U E P R I O R I T I Z A T I O N
The immediate need for a patient with suspected
NSCLC is to obtain a tissue diagnosis from a suitable
biopsy. This is best accomplished by a histopatholo-
gist viewing a haematoxylin and eosin-stained sec-
tion, or preferably a series of sections. Most pathology
departments therefore cut a series of sections and
stain several at different levels for histopathology,
while retaining intervening sections for IHC. If there
is morphological evidence of adenocarcinoma or
squamous differentiation, IHC is not required unless
there is a question regarding the primary site of ori-
gin. Where there is no morphological evidence of
squamous or glandular differentiation, a limited IHC
panel (e.g. p40 and thyroid transcription factor-1) is
recommended, with classification according to the
World Health Organization criteria for non-resection
samples.21 This should reduce the number of cases
classified as ‘NSCLC not otherwise specified’ to <10%.
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We therefore propose that tissue sections for PD-L1
IHC should be taken at the same time as those for
diagnostic IHC (if the latter is required) or later for
IHC for ALK and other predictive markers (e.g. EGFR
and ROS1), according to the preference of the multi-
disciplinary team. It is important to ensure that suffi-
cient material is left within the block for sections to
be cut for mutational analysis. The process is summa-
rized in Figure 2.
Analytical considerations
C H O I C E O F B I O M A R K E R K I T A N D A U T O M A T E D
S T A I N I N G P L A T F O R M
Companion PD-L1 IHC assays/kits are available or
in development, corresponding to different
checkpoint inhibitors for the treatment of PD-L1-
positive NSCLC (Table 1). Companion diagnostic
assays/kits allow greater standardization of PD-L1
IHC staining, and remove the potential uncertainties
or pitfalls associated with laboratory-devised tech-
niques (LDTs). Data from the UK National External
Quality Assessment Service for Immunocytochem-
istry and In Situ Hybridization (UK NEQAS ICC &
ISH) show that laboratories using standardized
assays outperform those using LDTs in ALK IHC
assessments for NSCLC.22 The assays have been
developed with corresponding staining methodolo-
gies, and are automated platform-specific. Laborato-
ries must adhere to the recommended staining
protocols of the manufacturer, as protocol modifica-
tions might lead to false-positive or false-negative
PD-L1 results. Before the introduction of a new
= Reflex molecular testing
= Molecular testing on request
SAMPLE
Undifferentiated NSCC on H&E
NSCC favours ADC
NSCC favours SQCC
NSCC NOS
NSCC ?LCNEC
NSCC ?ADSQCC
other
Diagnostic IHC panel
TTF-1
p40 (or p63 or CK5/6)
*CD56, chromogranin,
synaptophysin only if there is
suggestion of neuroendocrine
morphology
*other IHC only if there is a 
question as to primary site
not being lung
Diagnostic IHC, if appropriate
TTF-1
CD56
Chromogranin
Synaptophysin
MNF116
Therapy-related IHC 
if appropriate
ALK
PD-L1
(ROS1)
ADC, SQCC on H&E
MOLECULAR TESTING
Current therapies
(e.g EGFR)
Clinical trials
SCLC or carcinoid on H&E
MDT review
TREATMENT
Figure 2. Potential place of programmed death ligand 1 (PD-L1) testing in diagnostic immunohistochemistry (IHC) and the molecular
pathology of non-small-cell lung cancer. ADC, adenocarcinoma; ADSQCC, adeno-squamous carcinoma; ALK, anaplastic lymphoma kinase;
EGFR, epidermal growth factor receptor; H&E, haematoxylin and eosin; LCNEC, large-cell neuroendocrine carcinoma of the lung; MDT, mul-
tidisciplinary team; NOS, not otherwise specified; NSCC, non-small-cell carcinoma; ROS1, c-ros oncogene 1 receptor tyrosine kinase; SCLC,
small-cell lung cancer; SQCC, squamous cell carcinoma; TTF-1, thyroid transcription factor-1.
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diagnostic test into routine clinical service, laborato-
ries must follow one of two processes:23
• Verification of standardized kit assays.
• Validation of LDTs (including antibody dilution,
epitope retrieval and detection methods), with robust
methodology in an appropriate sample size, in order
to ensure reproducibility.
T R A I N I N G A N D I N T E R P R E T A T I O N
It will be critical for pathologists and scientists to
undertake relevant training on the companion diag-
nostic assay and its expected staining profile, and the
cut-offs associated with the drug under consideration.
Interpretive training should incorporate samples
showing the full range of PD-L1 IHC staining, includ-
ing known negative and positive NSCLC cases.
Interobserver variability in PD-L1 staining interpre-
tation should be strictly monitored, with the recom-
mendation that potential interpreters should review a
sufficient number of cases to achieve a minimum
concordance of 95%24 (in contrast to US guidelines,
in which a concordance rate of 90% is deemed
acceptable).
Quality assurance
Quality assurance is a requirement for all UK-accre-
dited clinical laboratories, with many laboratories
now undergoing transition from the UK Accreditation
Service (UKAS) to the ISO15189 standard. All
procedures for verification or validation must be doc-
umented in a standard operating procedure, and the
clinical laboratory should also consider other aspects
of uncertainty of measurement, such as:25,26
• The measuring instrument (maintenance and
calibration).
• The object being measured (is the measured
property stable?).
• The measurement process (tumour size in three
dimensions).
• The environment (temperature, air pressure, and
humidity).
• Sampling issues.
• The operator’s skill and judgement.
C O N T R O L S
Even though companion assays are standardized and
optimized, there may still be batch-to-batch variability
with reagents, and unforeseen issues with automated
staining platforms. It is therefore recommended that
laboratories should include controls alongside their
clinical cases being tested for PD-L1, to ensure that
the sensitivity and specificity of the test are satisfac-
tory. Ideally, NSCLC controls should be used, showing
at least positive and negative PD-L1 expression. The
use of controls with staining results close to the deci-
sion-making cut-off points is also recommended. Ide-
ally control sections should be cut at the same time
as the test material, and should be similarly fixed and
processed. Long-term storage of pre-cut control
Table 1. Programmed death ligand 1 (PD-L1) kits and platforms available for each anti-programmed death receptor 1 (PD-
1)-targeted or anti-PD-L1-targeted agent
Methodology Kit assay Automated platform Checkpoint inhibitor Target
Kit-based assay Dako 22C3 pharmDx Dako Autostainer Link 48 Pembrolizumab (MSD) PD-1
Dako PD-L1 IHC 28-8
pharmDx
Dako Autostainer Link 48 Nivolumab (BMS) PD-1
SP142: kit form TBC Ventana: TBC Atezolizumab (Roche) PD-L1
SP263: kit form TBC Ventana Benchmark platforms (GX, XT,
and Ultra)
Durvalumab (AstraZeneca/
MedImmune)
PD-L1
Standalone PD-L1
antibodies*
28-8 (RabMAb): BMS clone available from Abcam
E1L3N (RabMAb): Cell Signaling
SP142 (RabMAb): Spring Bioscience
TBC, to be confirmed.
*Not validated for clinical use.
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sections should be avoided. Commercial control sam-
ples and cell lines are becoming increasingly avail-
able, and these can be used as alternatives to tissue
samples. Commercial controls should also be cut onto
the same slide as the clinical samples.
E X T E R N A L Q U A L I T Y A S S U R A N C E
Any laboratory carrying out clinical PD-L1 IHC test-
ing must take part in an EQA as outlined by
ISO15189. An EQA for PD-L1 will provide informa-
tion on how well a laboratory’s assay has worked,
and any potential staining issues that may lead
to false-positive or false-negative results. The EQA
requires continuous participation; it helps labora-
tories to monitor their staining and interpretive
methods and, where required, provides individual
feedback to laboratories to improve staining
methodologies.
The UK NEQAS ICC & ISH, a not-for-profit organi-
zation that develops EQA modules covering numerous
areas of pathology, is currently in the planning stages
of a pilot PD-L1 EQA. The UK NEQAS ICC & ISH,
which is open to laboratories from all countries, mon-
itors UK participants for poor performance, and
reports persistent underperformers to the National
Quality Assurance Advisory Panel, which makes the
final decision on whether a laboratory may continue
to perform clinical IHC testing.
A U D I T
The expected PD-L1 positivity rate in the UK is cur-
rently unknown, and national data (acknowledging
regional variations) should be collected. Individual
laboratories must also audit their positivity rates in
order to highlight technical issues and the sensitivity
and specificity of different batches of PD-L1 assays.
I N T E R P R E T A T I O N
It is important to provide PD-L1 IHC results as part of
an integrated report, including the histopathological
diagnosis, the results of IHC to type the tumour, and
mutation analysis. Given the constraints of existing
laboratory information management systems and
electronic patient records, this is often a considerable
challenge. For PD-L1 IHC, the report should contain
the proportion of neoplastic cells staining positively.
For one of the drugs in development, the biomarker
test is based on the area of tumour infiltrated by PD-
L1-positive immune cells, including tumour-infiltrat-
ing (non-neoplastic) cells. Current evidence suggests
that the intensity of staining is not critical. Figure 3
shows the results of PD-L1 IHC staining.
Responses to this class of drugs have been seen in
patients showing all levels of PD-L1 expression, and,
for each drug and companion test, the thresholds
defining a ‘positive’ test result are different. It would
seem sensible to simplify as much as possible the crite-
ria for considering any individual tumour to be ‘posi-
tive’ or ‘negative’ for PD-L1 expression. The use of a
simple percentage cut-off for expression, irrespective of
intensity or other subjective features, is welcome to
minimize the number of cases that cross the threshold
as a result of technical variability (e.g. owing to differ-
ences in staining techniques resulting in variation in
intensity). Assays confined to the assessment of neo-
plastic cells would also be pragmatic. Such an
Figure 3. Three fields from the same section of a resected adenocar-
cinoma of the lung showing expression of programmed death
ligand 1 as detected by the Dako 22C3 antibody. The spatial
heterogeneity and variable pattern of expression are well shown.
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approach should be applicable to both cytology and
histology specimens, which is an important considera-
tion given that endobronchial ultrasound-guided aspi-
rates are now increasingly being used in the
combined diagnosis and staging of lung cancer. How-
ever, it should be noted that cytology samples were
never used in the validating clinical trials, so none of
the assays is technically validated for use on these
types of sample. Recent work has shown that at least
three of the companion diagnostic assays available
(based on the 28-8, 22C3 and SP263 clones) are tech-
nically comparable on the same tissues, whereas an
assay based on SP142 was less concordant.27 We will
need more data before any recommendation can be
made on use of anything other than a trial-proven
assay in association with a drug.
Areas for further research
To ensure that PD-L1 testing is introduced effectively
into routine clinical practice, several issues need to be
addressed in research, including:
• Relevance of tissue source and sample quality.
• Heterogeneity of PD-L1 expression within the
tumour, between primary and metastatic lesions and
over time.
• Impact of prior lines of treatment on PD-L1
expression.
• Optimal cut-offs identifying appropriate patient
populations for treatment.
• National and regional rates of PD-L1 positivity.
• Reproducibility and concordance of companion
diagnostic kits and platforms, including minimum
number of cases per year to ensure consistency of
interpretation, and applicability to the different drugs
available or in development—a cross-industry collab-
orative project is underway to agree and deliver ‘a
package of information/data upon which analytic
comparison of the various diagnostic assays may be
conducted, potentially paving the way for post-mar-
ket standardization and/or practice guideline develop-
ment as appropriate’.28
• Validation of LDTs.
• Role of TILs and/or staining intensity in
interpretation.
• Role of digital pathology.
Conclusions
Immunotherapy for cancer is now a reality. The drugs
involved are expensive, and will be used in concert
with existing treatment modalities, as well as with
other new drugs targeting molecular pathways. To
maximize clinical benefits, the challenge is to stratify
patients adequately following tissue diagnosis, and PD-
L1 IHC may be a requirement for patients with NSCLC.
In this article, we have set out a pathway for standard-
izing PD-L1 IHC as an important first step towards
integration of PD-L1 into locally agreed protocols for
pathology testing and treatment decision-making. As
immunotherapy progresses from research to routine
clinical use, there remain considerable areas of uncer-
tainty, and guidance should be updated regularly as
new information becomes available.
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